MovDisordV3, Main, Exploration, bibRecord, 005715

Acute pharmacologic blockade of dyskinesias in Parkinson's disease

Identifieur interne : 005715 ( Main/Exploration ); précédent : 005714; suivant : 005716

Acute pharmacologic blockade of dyskinesias in Parkinson's disease

Auteurs : Pierre J. Blanchet [États-Unis] ; Leo Verhagen Metman [États-Unis] ; M. Maral Mouradian [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1996-09.

RBID : ISTEX:1AE004D10FF1E0AC84B081B1E59D8C0E2230B537

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Chimiothérapie, Dyskinésie, Effet secondaire, Etude cas, Homme, Lévodopa, Parkinson maladie, Toxicité, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Case study, Chemotherapy, Dextrorphan (administration & dosage), Dextrorphan (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Excitatory Amino Acid Antagonists (administration & dosage), Excitatory Amino Acid Antagonists (therapeutic use), Human, Humans, Levodopa, Levodopa (therapeutic use), Middle Aged, Movement Disorders (complications), Movement Disorders (drug therapy), Parkinson Disease (complications), Parkinson disease, Placebos, Secondary effect, Severity of Illness Index, Toxicity, Treatment.
MESH :
- chemical , administration & dosage : Dextrorphan, Excitatory Amino Acid Antagonists.
- chemical , therapeutic use : Dextrorphan, Excitatory Amino Acid Antagonists, Levodopa.
- complications : Movement Disorders, Parkinson Disease.
- drug therapy : Movement Disorders.
- Double-Blind Method, Drug Therapy, Combination, Humans, Middle Aged, Placebos, Severity of Illness Index.

Url:

https://api.istex.fr/document/1AE004D10FF1E0AC84B081B1E59D8C0E2230B537/fulltext/pdf

DOI: 10.1002/mds.870110516

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
</author>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1AE004D10FF1E0AC84B081B1E59D8C0E2230B537</idno>
<date when="1996" year="1996">1996</date>
<idno type="doi">10.1002/mds.870110516</idno>
<idno type="url">https://api.istex.fr/document/1AE004D10FF1E0AC84B081B1E59D8C0E2230B537/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003F17</idno>
<idno type="wicri:Area/Istex/Curation">003F17</idno>
<idno type="wicri:Area/Istex/Checkpoint">003C17</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8866502</idno>
<idno type="wicri:Area/PubMed/Corpus">004777</idno>
<idno type="wicri:Area/PubMed/Curation">004777</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004882</idno>
<idno type="wicri:Area/Ncbi/Merge">004C05</idno>
<idno type="wicri:Area/Ncbi/Curation">004C05</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C05</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:Area/Main/Merge">008821</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:96-0423275</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003340</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003484</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003416</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:Area/Main/Merge">008948</idno>
<idno type="wicri:Area/Main/Curation">005715</idno>
<idno type="wicri:Area/Main/Exploration">005715</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1996-09">1996-09</date>
<biblScope unit="vol">11</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="580">580</biblScope>
<biblScope unit="page" to="581">581</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1AE004D10FF1E0AC84B081B1E59D8C0E2230B537</idno>
<idno type="DOI">10.1002/mds.870110516</idno>
<idno type="ArticleID">MDS870110516</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dextrorphan (administration & dosage)</term>
<term>Dextrorphan (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia</term>
<term>Excitatory Amino Acid Antagonists (administration & dosage)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Movement Disorders (complications)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson disease</term>
<term>Placebos</term>
<term>Secondary effect</term>
<term>Severity of Illness Index</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dextrorphan</term>
<term>Excitatory Amino Acid Antagonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dextrorphan</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Dyskinésie</term>
<term>Effet secondaire</term>
<term>Etude cas</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Toxicité</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
</region>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
<name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005715 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005715 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1AE004D10FF1E0AC84B081B1E59D8C0E2230B537
   |texte=   Acute pharmacologic blockade of dyskinesias in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Acute pharmacologic blockade of dyskinesias in Parkinson's disease

Acute pharmacologic blockade of dyskinesias in Parkinson's disease

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.